Search results for "Fibrillation"

showing 10 items of 509 documents

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

2014

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥75), and the overall population (All) from a US Medicare payer perspective. Clinical event rates by age cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY). An economic model was adapted using these data to evaluate the impact of starting age on clinical and economic outcomes. Costs were obtained from Medicare p…

Malemedicine.medical_specialtyTime FactorsCost effectivenessCost-Benefit AnalysisMedicareAntithrombinsDrug Administration ScheduleDrug CostsDabigatranThromboembolismInternal medicineAtrial FibrillationmedicineHumansIn patientcardiovascular diseasesStrokeAgedbusiness.industryIncidenceFollow up studiesWarfarinSystemic embolismAtrial fibrillationPrognosismedicine.diseaseUnited StatesDabigatranbeta-AlanineCardiologyBenzimidazolesFemalebusinessCardiology and Cardiovascular MedicineFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

Prognostic value of troponin I in atrial fibrillation

2021

To evaluate whether circulating cardiac troponin I (cTnI) levels are associated with worst outcomes in patients with atrial fibrillation (AF).Consecutive patients visiting the emergency room (ER) with a new episode of a previously diagnosed AF or a new diagnosis of AF during ER admission between January 1st, 2010 and December 31st, 2015, were enrolled in the study (n = 2617). After applying exclusion criteria and eliminating repeated episodes, 2013 patients were finally included. Of these, 1080 patients with at least one cTnI measurement in the ER were selected and classified into 4 groups according to cTnI quartiles: Q1 (n = 147) cTnI10 ng/L (Group 1); Q2 (n = 254): 10-19 ng/L (Group 2); Q…

Malemedicine.medical_specialtyTime FactorsHeart failureComorbidity030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineTroponin ImedicineClinical endpointAtrial fibrillation Emergency Heart failure Mortality TroponinsTroponinsHumans030212 general & internal medicineRisk factorMortalityAdverse effectAgedRetrospective StudiesAged 80 and overbiologybusiness.industryTroponin IAtrial fibrillationMiddle AgedPrognosismedicine.diseaseTroponinAtrial fibrillationQuartileHeart failureEmergencybiology.proteinFemaleEmergency Service HospitalCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring—Find-AFRANDOMISED —rationale and de…

2014

Background Detecting paroxysmal atrial fibrillation (AF) in patients with ischemic strokes presenting in sinus rhythm is challenging because episodes are often short, occur randomly, and are frequently asymptomatic. If AF is detected, recurrent thromboembolism can be prevented efficiently by oral anticoagulation. Numerous uncontrolled studies using various electrocardiogram (ECG) devices have established that prolonged ECG monitoring increases the yield of AF detection, but most established procedures are time-consuming and costly. The few randomized trials are mostly limited to cryptogenic strokes. The optimal method, duration, and patient selection remain unclear. Repeated prolonged conti…

Malemedicine.medical_specialtyTime FactorsPopulationAsymptomaticlaw.inventionRandomized controlled triallawGermanyInternal medicineMulticenter trialAtrial FibrillationPrevalencemedicineHumansSinus rhythmProspective Studiescardiovascular diseaseseducationStrokeAgededucation.field_of_studymedicine.diagnostic_testbusiness.industryIncidenceAtrial fibrillationmedicine.diseaseMagnetic Resonance Imaging3. Good healthSurgeryStrokeElectrocardiography AmbulatoryCardiologyFemalemedicine.symptomTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesAmerican Heart Journal
researchProduct

Relationship between HRV measurements and demographic and clinical variables in a population of patients with atrial fibrillation.

2015

Little is known about the role of HRV in atrial fibrillation (AF) patients. Aim of our study was to assess the relationship between HRV measurements and demographic and clinical variables in a population of 274 AF patients. We selected all consecutive patients with persistent/permanent AF among whom had performed a Holter ECG in our Department from April 2010 to April 2015. Time-domain analysis of HRV was evaluated. Demographic and clinical variables were collected for each patient. At multivariable logistic regression, a higher pNN50 was associated with ACE inhibitors/ARBs (p = 0.016) and a lower pNN50 with obesity (p = 0.037) and higher heart rate (HR) (p < 0.0005). A higher RMSSD w…

Malemedicine.medical_specialtyTime FactorsPopulationDigitalisComorbidity030204 cardiovascular system & hematologyAutonomic Nervous System03 medical and health sciences0302 clinical medicineHeart RateRisk FactorsInternal medicineHeart rateAtrial FibrillationmedicineHeart rate variabilityHumansSinus rhythm030212 general & internal medicineeducationStrokeHeart rate variabilityAgedRetrospective StudiesAged 80 and overeducation.field_of_studybiologybusiness.industryAtrial fibrillationHeartmedicine.diseasebiology.organism_classificationCardiac surgeryAntiarrhythmic drugCross-Sectional StudiesLogistic ModelsItalyMultivariate AnalysisCardiologyElectrocardiography AmbulatoryLinear ModelsPolypharmacyFemalebusinessCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsHolter ECGHeart and vessels
researchProduct

Impact of Midregional N‐Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treate…

2021

Background We assessed the impact of preprocedural plasma levels of MRproANP (midregional N‐terminal pro–atrial natriuretic peptide) and sST2 (soluble suppression of tumorigenicity 2) on recurrence of atrial fibrillation (AF) at 1 year after catheter ablation of AF. Methods and Results This was a prospective, multicenter, observational study including patients undergoing catheter ablation of AF. MRproANP and sST2 were measured in a peripheral venous blood preprocedure, and MRproANP was assessed in the right and left atrial blood during ablation. The primary end point was recurrent AF between 3 and 12 months postablation, defined as a documented (&gt;30 seconds) episode of AF, flutter, or a…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentBiorhythmCatheter ablation030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineHeart RatePredictive Value of TestsRecurrenceRisk FactorsInternal medicinecatheter ablationAtrial FibrillationmedicineNatriuretic peptideHumansIn patientArrhythmia and Electrophysiology030212 general & internal medicineHeart AtriaProspective StudiesOriginal ResearchAgedsST2business.industryMRproANPbiomarkersAtrial fibrillationPlasma levelsMiddle Agedmedicine.diseaseInterleukin-1 Receptor-Like 1 ProteinUp-RegulationHeart RhythmTreatment OutcomePro atrial natriuretic peptideCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCatheter Ablation and Implantable Cardioverter-DefibrillatorAtrial Natriuretic FactorJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Impact of biatrial defragmentation in patients with paroxysmal atrial fibrillation: Results from a randomized prospective study

2014

Single procedure success rates of pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF) are still unsatisfactory. In patients with persistent atrial fibrillation (AF), ablation of complex fractionated atrial electrograms (CFAEs) after PVI results in improved outcomes.We aimed to investigate if PAF-patients with intraprocedurally sustained AF after PVI might benefit from additional CFAE ablation.A total of 1134 consecutive patients underwent a first catheter ablation procedure of PAF between June 2008 and December 2012. In most patients, AF was either not inducible or terminated during PVI. In 68 patients (6%), AF sustained after successful PVI. These patients …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentElectric CountershockCatheter ablationCardioversionPulmonary veinHeart Conduction SystemHeart RatePhysiology (medical)Internal medicineAtrial FibrillationmedicineHumansSinus rhythmProspective StudiesTachycardia ParoxysmalProspective cohort studyAtrial tachycardiabusiness.industryAtrial fibrillationMiddle Agedmedicine.diseaseAblationTreatment OutcomePulmonary VeinsAnesthesiaCatheter AblationCardiologyFemalemedicine.symptomElectrophysiologic Techniques CardiacCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesHeart Rhythm
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) &amp;lt;65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients

2021

The association between the use of vitamin K antagonists (VKAs) and cancer risk reduction remains unclear. We aimed to assess the association between the use of VKAs or direct oral anticoagulants (DOACs) and the incidence of cancer in a large cohort of patients with atrial fibrillation (AF) by means of a population-based, propensity-weighted cohort study using population-wide databases including patients diagnosed with nonvalvular AF (NVAF) followed for up of 5 years (median 2.94 years). We created two cohorts based on the initiation therapy (VKA or DOAC). Initiation with VKA or DOAC was defined as filling a prescription with no previous exposure in the preceding 12 months. Cancer diagnoses…

Malemedicine.medical_specialtyVitamin KColorectal cancerKaplan-Meier EstimateLower riskGastroenterologyRisk AssessmentTHERAPYWARFARINCohort StudiesFibrinolytic AgentsRisk FactorsInternal medicineNeoplasmsAtrial FibrillationmedicineHumansPharmacology (medical)Correlation of DataAgedProportional Hazards ModelsPharmacologyRISKbusiness.industryIncidence (epidemiology)IncidenceHazard ratioCancerAnticoagulantsAtrial fibrillationmedicine.diseasePROSTATE-CANCERCohortFemalebusinessCohort studyFollow-Up Studies
researchProduct

Experience in daily clinical practice of ambulatory cardioversion of atrial fibrillation treated with new oral anticoagulants.

2014

Malemedicine.medical_specialtyVitamin Kbusiness.industrymedicine.medical_treatmentElectric CountershockAdministration OralAnticoagulantsAtrial fibrillationGeneral Medicinemedicine.diseaseCardioversionClinical PracticeThromboembolismAmbulatoryAtrial FibrillationmedicineAmbulatory CareHumansFemaleIntensive care medicinebusinessAgedRetrospective StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct